EB-101
Phase 3Biologic
EB-101 is one of 12 biologic programs targeting Recessive Dystrophic Epidermolysis Bullosa. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Recessive Dystrophic Epidermolysis Bullosa
#DrugCompanyPhaseTrials
1Fludara
SanofiPhase 1
Mesenchymal Stromal Cells
Mario Negri Institute for Pharmacological ResearchPhase 2
Garamycin
SSchering-Plough
Phase 1
Kepivance
SSwedish Orphan Biovitrum
Phase 1
Prograf
VVeloxis Pharmaceuticals
Phase 1
Ativan
BBausch Health Americas, Inc.
Phase 1
Campath
GGenzyme, a Sanofi Company
Phase 1
Busulfex
Akero TherapeuticsPhase 1
Accutane
CConrado Roberto Hoffmann Filho
Phase 1
EB-101
AAbeona Therapeutics, Inc
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for EB-101. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- AAbeona Therapeutics, Inc